

HPV 31 poses a higher risk of precancer as compared to HPV 18.¹

You screen for HPV 18, so why not HPV 31?



Meet Tianna*

- 35 years old
- No medical conditions
- Lives a healthy lifestyle and believes in the importance of cervical cancer screening
- Has had Pap smears every 3 years from age 21 to 29 and co-testing with HPV and Pap every five years starting at age 30

Cervical cancer screening history.

- Normal cytology
- Negative for HPV 16 and 18
- Negative for high-risk HPV pool

Current results:

- Normal cytology
- Negative for HPV 16 and 18 and all other high-risk types
- Positive for HPV 31

*“I was worried when I first found out that I had HPV 31, one of the most risky types of HPV, and what it meant for my risk of cervical precancer. But my OB/GYN was very supportive and we were quickly able to discuss a plan.”**

Normal cytology

HPV 16 -

HPV 18 -

HPV 31 +




What does the data say?

In a multicenter clinical trial involving 33,000 patients, the immediate risk of having precancer or cancer among women aged ≥ 30 with **normal cytology** and positive for **HPV 31** was 8.4%.¹

This is similar to the risk associated with HPV 16 and is 3 times higher than the risk associated with HPV 18.¹

Immediate CIN3+ risk by HPV type in women ≥ 30 years with normal cytology¹



Adapted from Stoler MH et al. Gynecol Oncol. 2019;153(1):26–33.

Based on Tianna’s cervical cancer screening results, what would you do?

- Follow-up in 1 year
- Follow-up in 3 years
- Colposcopy/biopsy
- Use the ASCCP Risk-Based Management App
- I’m not sure, HPV 31 is new to me

*Names and/or medical information presented on this page do not represent real people or clinical information.






What do the guidelines say?

The 2019 ASCCP Risk-Based Management Consensus Guidelines for the management of cervical cancer screening abnormalities recommend 1 of 6 clinical actions, according to the risk of cervical precancer and cancer (CIN3+ risk).²

Tianna's personalized immediate CIN3+ risk is **8.4%**¹ which calls for colposcopy as next step, based on the ASCCP guidelines.²



Why is individually identifying HPV 31 better for your patients?

HPV 31 poses a higher risk of precancer as compared to HPV 18 and should be identified individually.¹

Not all HPV tests are the same.

BD Onclarity™ HPV Assay is the only FDA-approved HPV test that provides an individual result for HPV 31.^{1,3-8}

Most HPV tests cannot identify which HPV type is causing the infection apart from HPV 16 and 18, and group the other high-risk types (including HPV 31) in one pooled result.⁹ This may underestimate the true CIN3+ risk due to HPV 31.^{1,10}

You screen for HPV 16 and 18, so why not HPV 31? Learn more on womens-health-solutions.bd.com



Different HPV types carry different risk. By using a test that can individually identify more HPV types, including HPV 31, you offer your patients a more precise cervical cancer risk assessment compared to an HPV test with grouped results.¹¹

*Names and/or medical information presented on this page do not represent real people or clinical information.

ASCCP, American Society for Colposcopy and Cervical Pathology; CIN3+, cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ, or cancer; FDA, Food and Drug Administration; HPV, human papillomavirus.

References: 1. Stoler MH et al. *Gynecol Oncol.* 2019;153(1):26–33. 2. Perkins RB et al. *J Low Genit Tract Dis.* 2020;24(2):102–31. 3. BD Onclarity™ HPV Assay US Package Insert [8089894]. 4. Aptima™ HPV Assay US Package Insert. 5. Cervista™ HPV HR US Package Insert. 6. cobas® HPV for 4800 System US Package Insert. 7. cobas® HPV for 6800/8800 System US Package Insert. 8. digene® HC2 High-Risk HPV DNA Test Package Insert. 9. Bonde J et al. *J Low Genit Tract Dis.* 2020;24(1):1–13. 10. Egemen D et al. *J Low Genit Tract Dis.* 2020;24(2):132–43. 11. Bonde J et al. *J Low Genit Tract Dis.* 2021;25(1):27–37.



bd.com

BD Life Sciences,
7 Loveton Circle, Sparks, MD 21152-0999, U.S.
Tel: 1.800.638.8663

BD, the BD Logo and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved. (BD-85054 2169-US-0523 March 2023)